Evidence map›Paper›PMID 32920022›Full record

Trial reportKidney international2021

Subgroup analysis of the ASPirin in Reducing Events in the Elderly randomized clinical trial suggests aspirin did not improve outcomes in older adults with chronic kidney disease.

Rory Wolfe, James B Wetmore, Robyn L Woods, John J McNeil, Hugh Gallagher, Paul Roderick, Rowan Walker, Mark R Nelson, Christopher M Reid, Raj C Shah and 12 more

Open access · greenAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Kidney international, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 2 pooled it
2.5field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 2 syntheses or guidelines pooled it, 28 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Use of Aspirin and Initial Cardiovascular and Bleeding Risk in Patients with Chronic Kidney Disease.Clinical journal of the American Society of Nephrology : CJASN · 2025
    Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

22 authors at 11 institutions in 3 countries.

Rory WolfeDepartment of Epidemiology and Preventive Medicine, Monash University, Melbourne, Victoria, Australia.
James B WetmoreDepartment of Medicine, Hennepin Healthcare Systems, Minneapolis, Minnesota, USA; Chronic Disease Research Group, Hennepin Healthcare Research Institute, Minneapolis, Minnesota, USA.
Robyn L WoodsDepartment of Epidemiology and Preventive Medicine, Monash University, Melbourne, Victoria, Australia.
John J McNeilDepartment of Epidemiology and Preventive Medicine, Monash University, Melbourne, Victoria, Australia.
Hugh GallagherRenal Services, Epsom and St Helier University Hospitals NHS Trust, London, UK.
Paul RoderickSchool of Primary Care, Population Sciences and Medical Education, University of Southampton and Southampton General Hospital, Hampshire, UK.
Rowan WalkerDepartment of Epidemiology and Preventive Medicine, Monash University, Melbourne, Victoria, Australia.
Mark R NelsonMenzies Institute for Medical Research, University of Tasmania, Hobart, Tasmania, Australia.
Christopher M ReidDepartment of Epidemiology and Preventive Medicine, Monash University, Melbourne, Victoria, Australia; School of Public Health, Curtin University, Perth, Western Australia, Australia.
Raj C ShahDepartment of Family Medicine and Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, Illinois, USA.
Michael E ErnstDepartment of Pharmacy Practice and Science, College of Pharmacy and Department of Family Medicine, Carver College of Medicine, University of Iowa, Iowa City, Iowa, USA.
Jessica E LockeryDepartment of Epidemiology and Preventive Medicine, Monash University, Melbourne, Victoria, Australia.
Andrew M TonkinDepartment of Epidemiology and Preventive Medicine, Monash University, Melbourne, Victoria, Australia.
Walter P AbhayaratnaCollege of Medicine, Biology and Environment, Australian National University, Canberra, Australian Capital Territory, Australia.
Peter GibbsWalter and Eliza Hall Institute of Medical Research, Melbourne, Victoria, Australia.
Erica M WoodDepartment of Epidemiology and Preventive Medicine, Monash University, Melbourne, Victoria, Australia.
Suzanne E MahadyDepartment of Epidemiology and Preventive Medicine, Monash University, Melbourne, Victoria, Australia; Department of Gastroenterology, Royal Melbourne Hospital, Melbourne, Victoria, Australia.
Jeff D WilliamsonSticht Center on Healthy Aging and Alzheimer's Prevention, Section on Gerontology and Geriatric Medicine, Department of Internal Medicine, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA.
Geoffrey A DonnanMelbourne Brain Centre, Royal Melbourne Hospital, University of Melbourne, Parkville, Victoria, Australia.
Geoffrey C CloudDepartment of Clinical Neurosciences, Central Clinical School, Monash University and Alfred Hospital, Melbourne, Victoria, Australia.
Anne M MurrayDepartment of Medicine, Hennepin Healthcare Systems, Minneapolis, Minnesota, USA.
Kevan R PolkinghorneDepartment of Epidemiology and Preventive Medicine, Monash University, Melbourne, Victoria, Australia; Department of Nephrology, Monash Medical Centre, Monash Health, Melbourne, Victoria, Australia. Electronic address: kevan.polkinghorne@monash.edu.
Monash University · AUHennepin Healthcare Research Institute · USAustralian National University · AUEpsom and St Helier University Hospitals NHS Trust · GBRush University Medical Center · USThe Royal Melbourne Hospital · AUUniversity of Iowa · USUniversity of Southampton · GBUniversity of Tasmania · AUWake Forest University · USWalter and Eliza Hall Institute of Medical Research · AU

Funding

ASPirin in Reducing Events in the ElderlyU01AG029824 · NIA · HENNEPIN HEALTHCARE RESEARCH INSTITUTE · PI MCNEIL, JOHN JAMES, MURRAY, ANNE M · 2009 to 2018
$64.6M
Main Administrative CoreU19AG062682 · NIA · HENNEPIN HEALTHCARE RESEARCH INSTITUTE · PI CHAN, ANDREW T, MCNEIL, JOHN JAMES · 2019 to 2023
$42.9M
Research Education CoreP30AG024824 · NIA · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Neil Alexander · 2004 to 2026
$29.2M
NIA NIH HHS P30 AG024824NIA NIH HHS U01 AG029824NIA NIH HHS U19 AG062682
6 · The paper itself

Abstract

The role of aspirin for primary prevention in older adults with chronic kidney disease (CKD) is unclear. Therefore, post hoc analysis of the randomized controlled trial ASPirin in Reducing Events in the Elderly (ASPREE) was undertaken comparing 100 mg of enteric-coated aspirin daily against matching placebo. Participants were community dwelling adults aged 70 years and older in Australia, 65 years and older in the United States, all free of a history of dementia or cardiovascular disease and of any disease expected to lead to death within five years. CKD was defined as present at baseline if either eGFR under 60mL/min/1.73m

Indexed as

Cardiovascular DiseasesRenal Insufficiency, ChronicAgedAged, 80 and overAspirinAustraliaHemorrhageHumansUnited StatesAspirinaspirinbleedingcardiovascular eventschronic kidney diseaseelderlyrandomized clinical trial

Identifiers

PMID32920022
PMCPMC7957958
OpenAlexW3083865301

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.